<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="69001">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02149940</url>
  </required_header>
  <id_info>
    <org_study_id>S55301</org_study_id>
    <nct_id>NCT02149940</nct_id>
  </id_info>
  <brief_title>Feasibility of Pharmaceutical Interventions in Elderly Heart Failure Patients.</brief_title>
  <acronym>RASP-HF</acronym>
  <official_title>Feasibility of Pharmaceutical Interventions in Elderly Heart Failure Patients: a Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure therapies (e.g. beta blockers) have been successful in decreasing mortality
      rates, as well as diminishing hospitalizations. Also, pharmacist collaboration has been
      shown to have a beneficial impact on heart failure related outcomes. Regardless, a high
      residual event rate is to be noted.

      In our pilot study, we wished to document whether a clinical pharmacist could still play a
      role in the heart failure management of an elderly inpatient heart failure population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research</study_design>
  <primary_outcome>
    <measure>the number of heart-failure related pharmaceutical interventions</measure>
    <time_frame>during hospital stay (average of 14 days)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>acceptance rate of the pharmaceutical interventions</measure>
    <time_frame>during hospital stay (average of 14 days)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical feasibility of the accepted interventions</measure>
    <time_frame>during hospital stay (average of 14 days)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>clinical pharmacy intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>heart-failure related pharmaceutical intervention</intervention_name>
    <arm_group_label>clinical pharmacy intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  75 years or older

          -  diagnosis of previous or new heart failure based on signs and symptoms as  defined by
             the 'European Society of Cardiology guidelines on acute and chronic heart failure'

          -  diagnosis had to be confirmed  by a recent echocardiogram

        Exclusion Criteria:

          -  not Dutch speaking

          -  treatment restrictions had been applied on admission
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karolien Walgraeve, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lorenz R Van der Linden, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jos Tournoy, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospitals Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Flemish Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 26, 2014</lastchanged_date>
  <firstreceived_date>May 26, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Elderly</keyword>
  <keyword>Frailty</keyword>
  <keyword>Polypharmacy</keyword>
  <keyword>Medication review</keyword>
  <keyword>Clinical pharmacy services</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
